The cumulative prevalence of HIV-1 drug resistance in perinatal HIV
Despite improved ART efficacy, DRMs limit treatment options, including long-acting injectable therapies with one-third having NNRTI-DRMs. Outcomes for second-generation INSTIs are promising with low rates of resistance but require continued monitoring. While multidrug resistance rates are lower in those born post2000, over one-third already have DRMs, highlighting the ongoing need for patient-centered approaches addressing adherence and novel ART class development.
Authors
- Jessica Glenn
- Aisleen Bennett (ORCID: https://orcid.org/0000-0003-4240-1972)
- Graham P. Taylor (ORCID: https://orcid.org/0000-0002-3773-2390)
- Sarah Fidler (ORCID: https://orcid.org/0000-0003-1676-7583)
- Caroline Foster (ORCID: https://orcid.org/0000-0001-8278-8564)
- Hermione Lyall (ORCID: https://orcid.org/0000-0001-6114-7215)
- Nicola Mackie
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Imperial College London (GB)
Publication Details
- Journal
- AIDS
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1097/qad.0000000000004202
- Citations
- 5
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.98